Side-by-side comparison of AI visibility scores, market position, and capabilities
Santa Clara semiconductor manufacturer (NASDAQ: INTC) $53.1B FY2024 revenue; $18.8B net loss, Gelsinger resignation Dec 2024, Intel 18A foundry bet, losing CPU/GPU share to AMD and NVIDIA.
Intel Corporation is a Santa Clara, California-based semiconductor company — publicly traded on the NASDAQ (NASDAQ: INTC) as an S&P 500 Information Technology component — designing and manufacturing microprocessors, chipsets, graphics processors, FPGAs, Ethernet controllers, and AI accelerators for personal computers, data center servers, network infrastructure, and embedded applications through approximately 108,000 employees (reduced from 120,000 through 2024 workforce restructuring). Intel faces its most significant competitive and strategic challenge in its 55-year history: in fiscal year 2024, Intel reported revenues of $53.1 billion (-2% year-over-year) with a net loss of approximately $18.8 billion — reflecting $16.6 billion in goodwill and asset impairment charges related to Intel Foundry's strategic reassessment, the most severe annual loss in Intel's history. CEO Pat Gelsinger resigned in December 2024 (effectively forced out by the Intel board after 4 years of leading the IDM 2.0 / Intel Foundry turnaround strategy) — with David Zinsner and Michelle Johnston Holthaus serving as interim co-CEOs while the board searched for a permanent successor. Intel's IDM 2.0 strategy (building Intel Foundry as an external contract semiconductor manufacturer competing with TSMC and Samsung Foundry) consumed $20+ billion in capital expenditure annually to construct the Ohio One and Arizona Fab 52/62 fabs while Intel's own products (Core Ultra processors, Gaudi AI accelerator) lost market share to AMD Ryzen CPUs and NVIDIA's GPU dominance — leaving Intel financially strained from capital deployment while failing to reverse the competitive momentum losses in its product businesses.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.